Literature DB >> 12628060

Vagus Nerve Stimulation As Treatment for Epileptic Seizures.

Martin C. Salinsky1.   

Abstract

Vagus nerve stimulation is a unique therapy for epileptic seizures. Two randomized controlled trials in patients with medically refractory partial seizures have demonstrated efficacy, leading to US Food and Drug Administration approval of vagus nerve stimulation therapy in 1997. Extensive safety testing has not revealed significant effects on cardiac, respiratory, or gastrointestinal function, though recent reports of intraoperative asystole and sleep-related airway obstruction have raised concerns. Vagus nerve stimulation is indicated for adjunctive therapy of partial-onset seizures in children and individuals older than 12 years (Class I evidence). Based on controlled, randomized trials, approximately 30% of these patients can be expected to have at least a 50% decrease in overall seizure frequency. Vagus nerve stimulation efficacy is similar to that of several newer antiepileptic drugs when used in similar populations in controlled, randomized trials. Long-term follow-up studies suggest continued efficacy over more than 1 year (Class III evidence). Case series suggest similar or greater efficacy in younger children, and in patients with refractory generalized seizures, including those associated with the Lennox-Gastaut syndrome (Class III evidence). Vagus nerve stimulation is appropriate therapy for patients with medically refractory epileptic seizures who are not optimal candidates for resective epilepsy surgery.

Entities:  

Year:  2003        PMID: 12628060     DOI: 10.1007/s11940-003-0002-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  36 in total

1.  VNS therapy in clinical practice in children with refractory epilepsy.

Authors:  L Nagarajan; P Walsh; P Gregory; M Lee
Journal:  Acta Neurol Scand       Date:  2002-01       Impact factor: 3.209

2.  Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group.

Authors:  D Labar; J Murphy; E Tecoma
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Authors:  A G Marson; Z A Kadir; J L Hutton; D W Chadwick
Journal:  Epilepsia       Date:  1997-08       Impact factor: 5.864

4.  Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death.

Authors:  J F Annegers; S P Coan; W A Hauser; J Leestma; W Duffell; B Tarver
Journal:  Epilepsia       Date:  1998-02       Impact factor: 5.864

5.  Vagus nerve stimulation for the treatment of bilateral independent temporal lobe epilepsy.

Authors:  T M Alsaadi; K D Laxer; N M Barbaro; W J Marks; P A Garcia
Journal:  Epilepsia       Date:  2001-07       Impact factor: 5.864

6.  Vagus nerve stimulation induces a sustained anticonvulsant effect.

Authors:  M Takaya; W J Terry; D K Naritoku
Journal:  Epilepsia       Date:  1996-11       Impact factor: 5.864

Review 7.  The mechanism of action of vagus nerve stimulation for refractory epilepsy: the current status.

Authors:  K Vonck; K Van Laere; S Dedeurwaerdere; J Caemaert; J De Reuck; P Boon
Journal:  J Clin Neurophysiol       Date:  2001-09       Impact factor: 2.177

8.  Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome.

Authors:  M Frost; J Gates; S L Helmers; J W Wheless; P Levisohn; C Tardo; J A Conry
Journal:  Epilepsia       Date:  2001-09       Impact factor: 5.864

9.  The nature of epilepsy in the general population. I. Characteristics of patients receiving medication for epilepsy.

Authors:  Y M Hart; S D Shorvon
Journal:  Epilepsy Res       Date:  1995-05       Impact factor: 3.045

10.  Vagus nerve stimulation in 16 children with refractory epilepsy.

Authors:  J Lundgren; P Amark; G Blennow; L G Strömblad; L Wallstedt
Journal:  Epilepsia       Date:  1998-08       Impact factor: 5.864

View more
  1 in total

Review 1.  Surgical treatment of epilepsy.

Authors:  John W Miller; Shahin Hakimian
Journal:  Continuum (Minneap Minn)       Date:  2013-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.